Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset the ATLANTIS study: A randomized controlled trial

JAMA

Volumn 282, Issue 21, 1999, Pages 2019-2026

  Clark, Wayne M ^a,g   Wissman, Stanley ^b   Albers, Gregory W ^c   Jhamandas, Jack H ^d   Madden, Kenneth P ^e   Hamilton, Scott ^f  

^a Oregon Stroke Center   (United States)

^b Stucky Research Center   (United States)

^c STANFORD UNIVERSITY   (United States)

^d UNIVERSITY OF ALBERTA   (Canada)

^e MARSHFIELD CLINIC   (United States)

^f GENENTECH INC   (United States)

^g OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; PLACEBO;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STROKE;

EID: 0033485522     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.282.21.2019     Document Type: Article

References (15)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
2. Alberts MJ, Brass LM, Perry A, Webb D, Dawson DV. Evaluation times for patients with in-hospital strokes. Stroke. 1993;24:1817-1822.
3. Chiu D, Krieger D, Villar-Cordova C. Intravenous tissue plasminogen activator for acute ischemic stroke. Stroke. 1997;29:18-22.
4. Tanne D, Macsback H, Verro P, for the rt-PA in Clinical Practice Stroke Survey Group. Intravenous rt-PA therapy for stroke in clinical practice: a multi-center evaluation of outcome [abstract]. Stroke. 1998;29:288.
5. Hanson S, Brauer D, Anderson D, et al. Stroke treatment in the community: intravenous rt-PA in clinical practice. Neurology. 1998;50(suppl 4):A155-A156.
6. Albers G. Prospective, monitored, multi-center, post-approval experience with intravenous rt-PA for treatment of acute stroke [abstract]. Stroke. 1999;30: 244.
7. Clark W, Albers G, Madden K, Hamilton S. The rt-pPA (Alteplase) 0-6 hour acute stroke trial part A (A0276g). Stroke. In press.
8. Brott T, Adams H, Olinger C, et al. Measurements of acute cerebral infarction. Stroke. 1989;20:864-870.
9. Lyden P, Brott T, Tilley B, et al. Improved reliability of NIH Stroke Scale using video training. Stroke. 1990;25:2220-2226.
10. Hacke W, Kaste M, Fieshchi C, et al, for the ECASS Study Group. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. JAMA. 1995;274:1017-1025.
11. van Swieten JC, Koudstaal PJ, Visser MC, Scheuten HA. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1998;14:61-65.
12. Mahoney F, Barthel D. Functional evaluation: Barthel index. MD State Med J. 1965;14:61-65.
13. Jennett B, Bond M. Assessment of outcome after severe brain damage. Lancet. 1975;1:480-484.
14. Clark W, Williams B, Selzer K, Zweifler R, Saboiunjian L, for the Citicoline Stroke Study Group. Randomized efficacy trial of Citicoline in acute ischemic stroke. Stroke. In press.
15. Hacke W, Kaste M, Fieshchi C, et al, for the Second European-Australasian Acute Stroke Study Investigators. Randomized double-blind placebo-controlled trial of thrombolytic therapy with intravenous Alteplase in acute ischemic stroke (ECASS II). Lancet. 1998;352:1245-1251.